Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Medication Overuse Headache (MOH) and an Innovative Approach (COMOESTAS)

Continuous Monitoring of Medication Overuse Headache in Europe and Latin America: Development and STAndardization of an Alert and Decision Support System

Appropriate delivery of quality healthcare requires constant monitoring of the patient during follow up, particularly in the presence of chronic diseases. This approach can be further improved if leading edge tools supporting diagnosis, as well as prediction, identification and monitoring of adverse events are available. COMOESTAS aims to develop an innovative Information Communications Technology (ICT) system that allows patients with a chronic condition to receive continuous and personalized treatment. The whole system is based on an advanced, "all in one" Alerting and Decision Support System that follows patients from the diagnosis and supports the physician in managing the therapy, controlling relevant events impacting on patient safety and activating specific procedures if selected thresholds are exceeded. In the frame of chronic neurological disorders, Medication Overuse Headache (MOH) is a common condition and a major cause of disability. MOH is curable, but its outcome is hampered by a high risk of relapse. It is, therefore, a perfect example of a disorder that can benefit from an ICT-assisted approach developing innovative systems and services for monitoring chronic conditions. COMOESTAS goals will be achieved by improving and integrating the traditional paper headache diaries and calendars into an innovative ICT tool taking into account the complex issues that accompany this peculiar form of headache, which will make the patient a key node in the entire process.

Aperçu de l'étude

Statut

Complété

Intervention / Traitement

Description détaillée

It will be a multicentre parallel group study. The two arms of the clinical protocol will be 1) classic approach to MOH and 2) Interactive Electronic Patient Record (IEPR)-based approach to MOH.

Each arm will last 12 months.

MOH will be diagnosed according to the 2006 MOH-R criteria of the International Headache Society as reported below:

A. Headache present on > 15 days/month.

B. Regular overuse for > 3 months of one or more acute symptomatic drugs:

  1. Ergotamine, triptans, opioids or combination analgesic medications on > 10 days/month on a regular basis for > 3 months.
  2. Simple analgesics or any combination of ergotamine, triptans, analgesics or opioids on > 15 days/month on a regular basis for >3 months without overuse (> 10 days) of any single class alone.

C. Headache has developed or markedly worsened during medication overuse.

The IEPR approach will be preliminarily tested and validated in small groups of patients during months 6-12 (pilot validation).

Each patient will be evaluated over a period of 7 months.

Classic approach Visit 0: patient is examined and, if suspected to suffer from MOH, is asked to fill in a diary for a month in order to quantify parameters of MOH (days with headache, acute drugs consumed, etc.). Patient has to report that MOH-R criteria were fulfilled for the previous 2 months.

Visit 1: Patient returns to the Centre, diary data are analyzed and recorded, and, if criteria for MOH-R diagnosis are fulfilled and exclusion criteria are ruled out , patient is enrolled in COMOESTAS protocol.

Detoxification: following visit 1, patient undergoes detoxification according to the protocol in Appendix 1. In the subsequent 2 months the patient is instructed to record headache characteristics and consumption of symptomatic drugs on a paper diary.

Visit 2 (2 months after detoxification): patient is visited again; diary is checked; if therapy is successful (patient no longer overuses acute medications for headache) the patient is scheduled for a follow-up visit after 4 months. The patient is asked to keep up recording headache characteristics and consumption of symptomatic drugs on a paper diary for the next 4 months and informed about a telephone contact after 2 months.

Visit 3 (6 months after detoxification): patient is visited again, diary data are collected. Study ends.

IEPR approach Visit 0: patient is examined and, if the minimum data set of the IEPR for MOH is satisfied, the patients is asked to record the headache characteristics as well as acute drugs consumption on a paper diary for a month in order to assess baseline parameters of MOH (days with headache, acute drugs consumed, etc.).

Patient has to report that MOH-R criteria were fulfilled for the previous 2 months.

Visit 1: Patient returns to the Centre, diary data are analyzed and recorded, and, if criteria for MOH diagnosis are confirmed and criteria of exclusion are ruled out, patient is enrolled in COMOESTAS protocol .

Detoxification: following Visit 1, patient undergoes detoxification according to the same protocol adopted for the classic approach. During the detoxification phase, the patient is instructed to use the electronic diary and is then asked to fill the electronic diary on a regular basis (preferably daily or at least weekly) for the next 6 months.

Visit 2 (2 months after detoxification): patient is visited again; if therapy is successful (patient no longer overuses acute medications for headache), MOH diagnosis the patient is scheduled for a follow-up visit after 4 months and informed about a telephone contact after 2 months. The patient is asked to keep up filling the electronic diary for the next 4 months.

Visit 3: the patient is visited again. Study ends.

Type d'étude

Interventionnel

Inscription (Réel)

690

Phase

  • N'est pas applicable

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

Patients with MOH

Exclusion Criteria:

  1. a current diagnosis of co-existent, significant and complicating medical or psychiatric illnesses
  2. significant overuse of "pure" opioids (patients overusing combination drugs containing opioids are allowed), benzodiazepines, and barbiturates,
  3. overuse of alcohol and other drugs of addiction,
  4. current treatment with migraine prophylactic drugs
  5. inefficacy of previous adequate detoxification programmes
  6. inability to provide reliable information about medical history
  7. pregnancy or breast feeding
  8. inability to learn how to use paper or electronic diaries

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Soins de soutien
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Aucune intervention: Classic Approach
Patient fills in a paper diary in order to quantify parameters of MOH (days with headache, acute drugs consumed, etc.)
Expérimental: IEPR Approach
Patient has to use the electronic diary to record days with headache, acute drugs consumed, etc.

Adoption of Interactive Electronic Patient Record (IEPR) that consists of the following clinically-relevant main components:

  • Minimum Data Set for supporting the diagnosis
  • Electronic Diary with associated alerting system for monitoring the patient during the follow-up period
  • Second opinion system for improving the management

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Relapse Rate Follow up
Délai: 6 month
Relapse Rate 6 months after withdrawal of patients with medication overuse. Relapse will be defined as use of ergotamine, triptans, opioids or combination analgesic medications on > 10 days/month or use of simple analgesics or any combination of ergotamine, triptans, analgesics or opioids on > 15 days/month during the previous month, with the exclusion of month +1.
6 month

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Days with headache
Délai: 6 month
Number of days with headache before and after detoxification in the two arms (month -1 vs. month +6)
6 month
Days per month with migraine
Délai: 6 month
Number of days per month with migraine before and after detoxification in the two arms (month -1 vs. month +6)
6 month
MOH patients/total number of headache
Délai: 12 month
Number of MOH patients/total number of headache patients during the recruitment period (6-12 months ) of the two arms
12 month
MOH patients/total number of headache
Délai: 24 month
Number of MOH patients/total number of headache patients during the recruitment period (18-24 months ) of the two arms
24 month
Drop-outs
Délai: 24 month
Number of drop-outs in the two arms
24 month
Midas scores
Délai: 24 month
Changes in Midas scores in the two arms
24 month
HURT scores
Délai: 24 month
Changes in HURT scores in the two arms
24 month

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Directeur d'études: Giuseppe Nappi, MD, IRCCS Fondazione Istituto Neurologico Nazionale C. Mondino, Pavia, ITALY
  • Chercheur principal: Rigmor Jensen, MD, PhD, Glostrup Hospital, Copenaghen, Denmark
  • Chercheur principal: Zaza Katsarava, MD, PHD, MSc, Universitaetsklinikum, Essen, Germany
  • Chercheur principal: Jorge Leston, MD, Fundacion para la Lucha contra las Enfermedades Neurologicas de la Infancia, Argentina
  • Chercheur principal: Ricardo Fadic, MD, Pontificia Universidad Catolica de Chile
  • Chercheur principal: Miguel JA Lainez, MD, PhD, Fundacion de la Comunidad Valenciana para la Investigacion Biomedica, la Docencia Y la Cooperacion Internacional y para el Desarrollo del Hospital Clinico Universitario De Valencia, Spain
  • Chercheur principal: Marco Pagani, Manager, Consorzio di Bioingegneria Medica, Pavia, Italy
  • Chercheur principal: Nestor Gorini, Ministerio de la Salud de la Provincia de Buenos Aires, Argentina
  • Chercheur principal: Santiago Spadafora, Fundacion Isalud, Buenos Aires, Argentina

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 juillet 2008

Achèvement primaire (Réel)

1 juillet 2009

Achèvement de l'étude (Réel)

1 juin 2010

Dates d'inscription aux études

Première soumission

30 avril 2015

Première soumission répondant aux critères de contrôle qualité

5 mai 2015

Première publication (Estimation)

6 mai 2015

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Estimation)

6 mai 2015

Dernière mise à jour soumise répondant aux critères de contrôle qualité

5 mai 2015

Dernière vérification

1 avril 2015

Plus d'information

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

3
S'abonner